Breast cancer cell lines exhibit differential sensitivities to microtubule-targeting drugs independent of doubling time

Anticancer Research

Volumn 35, Issue 11, 2015, Pages 5845-5850

  Risinger, April L ^a   Dybdal Hargreaves, Nicholas F ^a   Mooberry, Susan L ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Docetaxel; Eribulin; Ixabepilone; Microtubule; Microtubule destabilize; Paclitaxel; Vinorelbine

Indexed keywords

DOCETAXEL; ERIBULIN; IXABEPILONE; NAVELBINE; PACLITAXEL; ANTIMITOTIC AGENT; TUBULIN MODULATOR;

ARTICLE; BREAST CANCER CELL LINE; CANCER CHEMOTHERAPY; CELL CULTURE; CELL DENSITY; CELL DIVISION; CONTROLLED STUDY; DOSE RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LC50; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; FLOW CYTOMETRY; MICROTUBULE; PATHOLOGY; TUMOR CELL CULTURE;

ANTIMITOTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; HUMANS; MICROTUBULES; TUBULIN MODULATORS; TUMOR CELLS, CULTURED;

EID: 84946070830     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Andreu JM, Diaz JF, Gil R, de Pereda JM, Garcia de Lacoba M, Peyrot V, Briand C, Towns-Andrews E and Bordas J: Solution structure of Taxotere-induced microtubules to 3-nm resolution. The change in protofilament number is linked to the binding of the taxol side chain. J Biol Chem 269: 31785-31792, 1994.
2. Binet S, Fellous A, Lataste H, Krikorian A, Couzinier JP and Meininger V: In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 16: 5-8, 1989.
3. Boyd MR and Paull KD: Some practical considerations and applications of the National Cancer Institute in vitro anticancer discovery screen. Drug Devel Res 34: 91-109, 1995.
4. Chittajallu DR, Florian S, Kohler RH, Iwamoto Y, Orth JD, Weissleder R, Danuser G and Mitchison TJ: In vivo cell-cycle profiling in xenograft tumors by quantitative intravital microscopy. Nat Methods 12: 577-585, 2015.
5. Dabydeen DA, Burnett JC, Bai R, Verdier-Pinard P, Hickford SJ, Pettit GR, Blunt JW, Munro MH, Gussio R and Hamel E: Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 70: 1866-1875, 2006.
6. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander NH, Nanus DM and Giannakakou P: Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 71: 6019-6029, 2011.
7. Dumontet C and Jordan MA: Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9: 790-803, 2010.
8. Dybdal-Hargreaves NF, Risinger AL and Mooberry SL: Eribulin Mesylate: Mechanism of action of a unique microtubuletargeting agent. Clin Cancer Res 21: 2445-2452, 2015.
9. Fabre C, Czaplicki J, Wright M, Hill B, Barret JM, Fahy J and Milon A: Differential binding to the alpha/beta-tubulin dimer of vinorelbine and vinflunine revealed by nuclear magnetic resonance analyses. Biochem Pharmacol 64: 733-740, 2002.
10. Fromes Y, Gounon P, Veitia R, Bissery MC and Fellous A: Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel. J Protein Chem 15: 377-388, 1996.
11. Goodin S, Kane MP and Rubin EH: Epothilones: mechanism of action and biologic activity. J Clin Oncol 22: 2015-2025, 2004.
12. Janssen A, Beerling E, Medema R and van Rheenen J: Intravital FRET imaging of tumor cell viability and mitosis during chemotherapy. PLoS One 8: e64029, 2013.
13. Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265, 2004.
14. Khrapunovich-Baine M, Menon V, Yang CP, Northcote PT, Miller JH, Angeletti RH, Fiser A, Horwitz SB and Xiao H: Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation. J Biol Chem 286: 11765-11778, 2011.
15. Komlodi-Pasztor E, Sackett D, Wilkerson J and Fojo T: Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 8: 244-250, 2011.
16. Komlodi-Pasztor E, Sackett DL and Fojo AT: Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res 18: 51-63, 2012.
17. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triplenegative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767, 2011.
18. Lobert S, Vulevic B and Correia JJ: Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 35: 6806-6814, 1996.
19. Mitchison TJ: The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 23: 1-6, 2012.
20. Orth JD, Kohler RH, Foijer F, Sorger PK, Weissleder R and Mitchison TJ: Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. Cancer Res 71: 4608-4616, 2011.
21. Parker AL, Kavallaris M and McCarroll JA: Microtubules and their role in cellular stress in cancer. Front Oncol 4: 153, 2014.
22. Poruchynsky MS, Komlodi-Pasztor E, Trostel S, Wilkerson J, Regairaz M, Pommier Y, Zhang X, Kumar Maity T, Robey R, Burotto M, Sackett D, Guha U and Fojo AT: Microtubuletargeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins. Proc Natl Acad Sci USA 112: 1571-1576, 2015.
23. Reszka AA, Seger R, Diltz CD, Krebs EG and Fischer EH: Association of mitogen-activated protein kinase with the microtubule cytoskeleton. Proc Natl Acad Sci USA 92: 8881-8885, 1995.
24. Rohena CC and Mooberry SL: Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities. Nat Prod Rep 31: 335-355, 2014.
25. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
26. Tinley TL, Leal RM, Randall-Hlubek DA, Cessac JW, Wilkens LR, Rao PN and Mooberry SL: Novel 2-methoxyestradiol analogues with antitumor activity. Cancer Res 63: 1538-1549, 2003.
27. Verweij J, Clavel M and Chevalier B: Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 5: 495-505, 1994.
28. Von Hoff DD: The taxoids: same roots, different drugs. Semin Oncol 24: S13-13-S13-10, 1997.